Table 2.
Cancer‐associated thrombosis treatment trials with direct oral anticoagulants
| Variable | Hokusai VTE Cancer | SELECT‐D | ADAM VTE | Caravaggio |
|---|---|---|---|---|
| Number of participants | 1,050 (1,046) | 406 | 300 (287) | 1,170 (1,155) |
| Study drug, n | Edoxaban, 522 | Rivaroxaban, 203 | Apixaban, 145 | Apixaban, 576 |
| Comparator drug, n | Dalteparin, 524 | Dalteparin, 203 | Dalteparin, 142 | Dalteparin, 579 |
| DVT only, n (%) | ||||
| Total | 389 (32.7) | 110 (27.1) | 106 (36.9) | 517 (44.7) |
| Study arm | 194 (37.2) edoxaban | 53 (26.1) rivaroxaban | 54 (36.7) apixaban | 272 (47.2) apixaban |
| Comparator arm | 195 (37.2) dalteparin | 57 (28.1) dalteparin | 52 (35.1) dalteparin | 245 (42.3) dalteparin |
| PE with or without DVT, n (%) | ||||
| Total | 657 (62.8) | 295 (72.6) | 156 (54.3) | 638 (55.2) |
| Study arm | 328 (62.8) edoxaban | 150 (73.9) rivaroxaban | 81 (55.9) apixaban | 304 (52.8) apixaban |
| Comparator arm | 329 (62.8) dalteparin | 145 (71.4) dalteparin | 75 (52.8) dalteparin | 334 (57.7) dalteparin |
| Incidental thrombosis, n (%) | ||||
| Total | 340 (32.5) | 213 (52.5) | Not reported in manuscript | 230 (19.9) |
| Study arm | 167 (32.0) edoxaban | 108 (53.2) rivaroxaban | 116 (20.1) apixaban | |
| Comparator arm | 173 (33.0) dalteparin | 105 (51.7) dalteparin | 114 (19.7) dalteparin | |
| Metastatic disease, n (%) | Or recurrent locally advanced | |||
| Total | 554 (53.0) | 236 (58.1) | 193 (67.2) | 785 (68.0) |
| Study arm | 274 (52.5) edoxaban | 118 (58.1) rivaroxaban | 96 (65.3) apixaban | 389 (67.5) apixaban |
| Comparator arm | 280 (53.4) dalteparin | 118 (58.1) dalteparin | 97 (66.0) dalteparin | 396 (68.4) dalteparin |
| VTE recurrence, n (%) | ||||
| Total | 100 (9.6) | 36 (8.9) | 10 (3.5) | 78 (6.8) |
| Study arm | 41 (7.9) edoxaban | 8 (3.9) rivaroxaban | 1 (0.7) apixaban | 32 (5.6) apixaban |
| Comparator arm | 59 (11.3) dalteparin | 18 (8.9) dalteparin | 9 (6.3) dalteparin | 46 (7.9) dalteparin |
| Major bleeding, n (%) | ||||
| Total | 57 (5.4) | 17 (4.2) | 2 (0.7) | 45 (3.9) |
| Study arm | 36 (6.9) edoxaban | 11 (5.4) rivaroxaban | 0 apixaban | 22 (3.8) apixaban |
| Comparator arm | 21 (4.0) dalteparin | 6 (3.0) dalteparin | 2 (1.4) dalteparin | 23 (4.0) dalteparin |
| CRNMB, n (%) | ||||
| Total | 134 (12.8) | 32 (7.9) | 16 (5.6) | 87 (7.5) |
| Study arm | 76 (14.6) edoxaban | 25 (12.3) rivaroxaban | 9 (6.2) apixaban | 52 (9.0) apixaban |
| Comparator arm | 58 (11.1) dalteparin | 7 (3.4) dalteparin | 7 (4.2) dalteparin | 35 (6.0) dalteparin |
| Deaths (any cause), n (%) | ||||
| Total | 399 (38.1) | 104 (25.6) | 38 (13.2) | 288 (24.9) |
| Study arm | 206 (39.5) edoxaban | 48 (23.6) rivaroxaban | 23 (16) apixaban | 135 (23.4) apixaban |
| Comparator arm | 193 (36.6) dalteparin | 56 (27.6) dalteparin | 15 (11) dalteparin | 153 (26.4) dalteparin |
Abbreviations: CRNMB, clinically relevant nonmajor bleeding; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism.